Clinical-stage biopharmaceutical company developing therapies for metabolic diseases, including Prader-Willi syndrome
Clinical-stage biopharmaceutical company developing therapies for metabolic diseases, including Prader-Willi syndrome. Its programs draw on proprietary knowledge of MetAP2 systems biology; ZGN-1258 was designed to reduce hyperphagia, alter fat metabolism, and reduce fat mass.